Skip to main content
Springer Nature Link
Log in

Prognostic usage of VH gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia

  • Review
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

B-cell chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease with many patients surviving for decades with minimal or no treatment, whereas others succumb rapidly to their disease despite therapy. In recent years, new molecular prognostic factors have emerged in CLL that have significantly improved the subgrouping of the disease. One of the most important molecular predictors, the immunoglobulin VH gene mutation status, divides CLL into two prognostic groups, depending on the presence or absence of somatic hypermutation, where unmutated VH genes are associated with considerably worse prognosis than mutated VH genes. An exception to this appears to be CLL patients utilizing the VH3-21 gene as they have poor outcome irrespective of mutation status. Surrogate markers for the VH gene mutation status have been suggested, such as CD38 and ZAP-70 expression. However, the CD38 level was later shown to display poor correlation to the mutation status, although it may still serve as an independent prognostic factor. More promising is the expression levels of ZAP-70, which appears to be both a strong surrogate marker for VH gene mutation status, although discrepancies have been reported, as well as an independent prognostic marker. Immunoglobulin gene analysis has also indicated the possibility of antigen selection in CLL considering the significant bias in VH gene usage. Intriguingly, the VH3-21+ group and several other CLL subsets using certain VH genes was recently reported to display strikingly restricted immunoglobulin gene features, in both their heavy and light chain gene rearrangements, thus further high-lighting the possible role of antigen involvement in CLL development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from $39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

References

  1. Matutes E, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8(10):1640–1645.

    PubMed  CAS  Google Scholar 

  2. Binet JL, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48(1):198–206.

    Article  PubMed  CAS  Google Scholar 

  3. Rai KR, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219–234.

    PubMed  CAS  Google Scholar 

  4. Damle RN, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94(6):1840–1847.

    PubMed  CAS  Google Scholar 

  5. Hamblin TJ, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848–1854.

    PubMed  CAS  Google Scholar 

  6. Tobin G, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99(6):2262–2264.

    Article  PubMed  CAS  Google Scholar 

  7. Crespo M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348(18):1764–1775.

    Article  PubMed  CAS  Google Scholar 

  8. Dohner H, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910–1916.

    Article  PubMed  CAS  Google Scholar 

  9. Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunol Today 1995;16(5):237–242.

    Article  PubMed  CAS  Google Scholar 

  10. Tonegawa S. Somatic generation of antibody diversity. Nature 1983;302(5909):575–581.

    Article  PubMed  CAS  Google Scholar 

  11. Alt FW, Baltimore D. Joining of immunoglobulin heavy chain gene segments: implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci USA 1982;79(13):4118–4122.

    Article  PubMed  CAS  Google Scholar 

  12. Sakano H, et al. Two types of somatic recombination are necessary for the generation of complete immunoglobulin heavy-chain genes. Nature 1980;286(5774):676–683.

    Article  PubMed  CAS  Google Scholar 

  13. Weigert M, et al. The joining of V and J gene segments creates antibody diversity. Nature 1980;283(5746):497–499.

    Article  PubMed  CAS  Google Scholar 

  14. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002;109(Suppl):S45–55.

    Article  PubMed  CAS  Google Scholar 

  15. Jung D, Alt FW. Unraveling V(D)J recombination; insights into gene regulation. Cell 2004;116(2):299–311.

    Article  PubMed  CAS  Google Scholar 

  16. Kelsoe G. The germinal center: a crucible for lymphocyte selection. Semin Immunology 1996;8(3):179–184.

    Article  CAS  Google Scholar 

  17. Papavasiliou FN, Schatz DG. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 2002;109(Suppl):S35–44.

    Article  PubMed  CAS  Google Scholar 

  18. Wagner SD, Neuberger MS. Somatic hypermutation of immunoglobulin genes. Annu Rev Immunol 1996;14:441–457.

    Article  PubMed  CAS  Google Scholar 

  19. Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 2000;13(1):37–45.

    Article  PubMed  CAS  Google Scholar 

  20. Kuppers R, Klein U, Hansmann M-L, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341(20):1520–1529.

    Article  PubMed  CAS  Google Scholar 

  21. Matsuda F, et al. Structure and physical map of 64 variable segments in the 3′0.8-megabase region of the human immunoglobulin heavy-chain locus. Nat Genet 1993;3(1):88–94.

    Article  PubMed  CAS  Google Scholar 

  22. Thorselius M, et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol 2002;68(4):217–224.

    Article  PubMed  CAS  Google Scholar 

  23. Rettig MB, et al. VH gene usage is multiple myeloma: complete absence of the VH4.21 (VH4- 34) gene. Blood 1996;87(7):2846–2852.

    PubMed  CAS  Google Scholar 

  24. Dono M, et al. Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. Blood 1996;87(4):1586–1594.

    PubMed  CAS  Google Scholar 

  25. Maloum K, et al. Analysis of VH gene expression in CD5+ and CD5- B-cell chronic lymphocytic leukemia. Blood 1995;86(10):3883–3890.

    PubMed  CAS  Google Scholar 

  26. Fais F, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102(8):1515–1525.

    Article  PubMed  CAS  Google Scholar 

  27. Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994;15(6):288–294.

    Article  PubMed  CAS  Google Scholar 

  28. Maloum K, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000;96(1):377–379.

    PubMed  CAS  Google Scholar 

  29. Thunberg U, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001;97(6):1892–1894.

    Article  PubMed  CAS  Google Scholar 

  30. Krober A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100(4):1410–1416.

    PubMed  CAS  Google Scholar 

  31. Oscier DG, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100(4):1177–1184.

    PubMed  CAS  Google Scholar 

  32. Guarini A, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003;102(3):1035–1041.

    Article  PubMed  CAS  Google Scholar 

  33. Tobin G, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: Implicating recognition of a common antigen epitope. Blood 2003;101(12):4952–4957.

    Article  PubMed  CAS  Google Scholar 

  34. Davis ZA, Orchard JA, Corcoran MM, Oscier DG. Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms. Blood 2003;102(8):3075.

    Article  PubMed  CAS  Google Scholar 

  35. Lin K, et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100(4):1404–1409.

    Article  PubMed  CAS  Google Scholar 

  36. Hamblin TJ, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99(3):1023–1029.

    Article  PubMed  CAS  Google Scholar 

  37. Dianzani U, et al. Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. J Immunol 1994;153(3):952–959.

    PubMed  CAS  Google Scholar 

  38. Hamblin TJ, et al. Immunoglobulin V genes and CD38 expression in CLL [letter]. Blood 2000;95(7):2455–2457.

    PubMed  CAS  Google Scholar 

  39. Jelinek DF, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001;115(4):854–861.

    Article  PubMed  CAS  Google Scholar 

  40. Matrai Z, et al. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood 2001;97(6):1902–1903.

    Article  PubMed  CAS  Google Scholar 

  41. Vilpo J, et al. Surface antigen expression and correlation with variable heavy-chain gene mutation status in chronic lymphocytic leukemia. Eur J Haematol 2003;70(1):53–59.

    Article  PubMed  CAS  Google Scholar 

  42. Morabito F, et al. Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. Leuk Res 2001;25(11):927–932.

    Article  PubMed  CAS  Google Scholar 

  43. Del Poeta G, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98(9):2633–2639.

    Article  PubMed  Google Scholar 

  44. Mainou-Fowler T, et al. Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol 2002;118(3):755–761.

    Article  PubMed  Google Scholar 

  45. Ibrahim S, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98(1):181–186.

    Article  PubMed  CAS  Google Scholar 

  46. Chevallier P, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002;116(1):142–150.

    Article  PubMed  CAS  Google Scholar 

  47. D’Arena G, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42(1–2):109–114.

    Article  PubMed  CAS  Google Scholar 

  48. Domingo-Domenech E, et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 2002;87(10):1021–1027.

    PubMed  Google Scholar 

  49. Durig J, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002;16(1):30–35.

    Article  PubMed  CAS  Google Scholar 

  50. Ghia P, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101(4):1262–1269.

    Article  PubMed  CAS  Google Scholar 

  51. Chang CC, Cleveland RP. Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course. Blood 2002;100(3):1106.

    Article  PubMed  CAS  Google Scholar 

  52. Heintel D, et al. Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia. Leuk Lymphoma 2001;42(6):1315–1321.

    Article  PubMed  CAS  Google Scholar 

  53. Dignum HM, Summerfield GP, Proctor SJ, Mainou-Fowler T. Quantification of CD38 expression in B-cell chronic lymphocytic leukemia (B-CLL): a comparison between antibody binding capacity (ABC) and relative median fluorescence (RMF). Leuk Lymphoma 2004;45(6):1167–1173.

    Article  PubMed  CAS  Google Scholar 

  54. Rosenwald A, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194(11):1639–1647.

    Article  PubMed  CAS  Google Scholar 

  55. Chen L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100(13):4609–4614.

    Article  PubMed  CAS  Google Scholar 

  56. Wiestner A, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101(12):4944–4951.

    Article  PubMed  CAS  Google Scholar 

  57. Orchard JA, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105–111.

    Article  PubMed  CAS  Google Scholar 

  58. Rassenti LZ, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351(9):893–901.

    Article  PubMed  CAS  Google Scholar 

  59. Admirand JH, et al. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 2004;17(8):954–961.

    Article  PubMed  CAS  Google Scholar 

  60. Durig J, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17(12):2426–2434.

    Article  PubMed  CAS  Google Scholar 

  61. Ferrer A, et al. Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2004;153(1):69–72.

    Article  PubMed  CAS  Google Scholar 

  62. Orchard JA, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363(9403):105–111.

    Article  PubMed  CAS  Google Scholar 

  63. Kim SZ, et al. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk Lymphoma 2004;45(10):2037–2045.

    Article  PubMed  CAS  Google Scholar 

  64. Dohner H, et al. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999;77(2):266–281.

    Article  PubMed  CAS  Google Scholar 

  65. Juliusson G, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323(11):720–724.

    Article  PubMed  CAS  Google Scholar 

  66. Dewald GW, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003;121(2):287–295.

    Article  PubMed  Google Scholar 

  67. Hernandez JM, et al. Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria. Leukemia 1995;9(12):2140–2146.

    PubMed  CAS  Google Scholar 

  68. Neilson JR, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11(11):1929–1932.

    Article  PubMed  CAS  Google Scholar 

  69. Auer RL, et al. Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2005;43(1):1–10.

    Article  PubMed  CAS  Google Scholar 

  70. Bullrich F, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999;59(1):24–27.

    PubMed  CAS  Google Scholar 

  71. Schaffner C, et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999;94(2):748–753.

    PubMed  CAS  Google Scholar 

  72. Dohner H, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85(6):1580–1589.

    PubMed  CAS  Google Scholar 

  73. el Rouby S, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82(11):3452–3459.

    PubMed  Google Scholar 

  74. Gaidano G, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88(12):5413–5417.

    Article  PubMed  CAS  Google Scholar 

  75. Fenaux P, et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992;6(4):246–250.

    PubMed  CAS  Google Scholar 

  76. Karhu R, et al. More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia. Genes Chromosomes Cancer 2003;37(4):417–420.

    Article  PubMed  Google Scholar 

  77. Kipps TJ, et al. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989;86(15):5913–5917.

    Article  PubMed  CAS  Google Scholar 

  78. Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire [see comments]. Immunol Today 1994;15(6):288–294.

    Article  PubMed  CAS  Google Scholar 

  79. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997;158(1):235–246.

    PubMed  CAS  Google Scholar 

  80. Rosenquist R, et al. V(H) gene family utilization in different B-cell lymphoma subgroups. Eur J Haematol 1999;62(2):123–128.

    Article  PubMed  CAS  Google Scholar 

  81. Potter KN, et al. Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood 2003;101(8):3082–3084.

    Article  PubMed  CAS  Google Scholar 

  82. Widhopf GF, 2nd, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004;104(8):2499–2504.

    Article  PubMed  CAS  Google Scholar 

  83. Lin K, et al. High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood 2003;102(3):1145–1146.

    Article  PubMed  CAS  Google Scholar 

  84. Matthews C, Catherwood M, Morris TC, Alexander HD. Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols. Leuk Lymphoma 2004;45(9):1899–1904.

    Article  PubMed  CAS  Google Scholar 

  85. Degan M, et al. Analysis of IgVH gene mutations in B-cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. Br J Haematol 2004;126(1):29–42.

    Article  PubMed  CAS  Google Scholar 

  86. Ghia P, et al. Geographic patterns and pathogenetic implications of IGHV gene sage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005;1045(4):1678–1685.

    Article  CAS  Google Scholar 

  87. Duke VM, et al. V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia. Haematologica 2003;88(11):1259–1271.

    PubMed  CAS  Google Scholar 

  88. Messmer BT, Albesiano E, Messmer D, Chiorazzi N. The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. Blood 2004;103(9):3490–3495.

    Article  PubMed  CAS  Google Scholar 

  89. Tobin G, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104(9):2879–2885.

    Article  PubMed  CAS  Google Scholar 

  90. Kolar GR, Capra JD. Ig V region restrictions in human chronic lymphocytic leukemia suggest some cases have a common origin. J Clin Invest 2004;113(7):952–954.

    Article  PubMed  CAS  Google Scholar 

  91. Valetto A, et al. A subset of IgG+ B-CLL cells expresses virtually identical antigen receptors that bind similar peptides. Blood 1998;92:A431.

    Google Scholar 

  92. Ghiotto F, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004;113(7):1008–1016.

    Article  PubMed  CAS  Google Scholar 

  93. Messmer BT, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200(4):519–525.

    Article  PubMed  CAS  Google Scholar 

  94. Martin T, et al. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J Immunol 1994;152(12):5988–5996.

    PubMed  CAS  Google Scholar 

  95. Tobin G, et al. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica 2005;90(4):465–469.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Sweden

    Gerard Tobin PhD & Richard Rosenquist

Authors
  1. Gerard Tobin PhD
    View author publications

    Search author on:PubMed Google Scholar

  2. Richard Rosenquist
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Gerard Tobin PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tobin, G., Rosenquist, R. Prognostic usage of VH gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. Med Oncol 22, 217–228 (2005). https://doi.org/10.1385/MO:22:3:217

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1385/MO:22:3:217

Key Words